DataM Intelligence | competitive Intelligence CIDP treatment evolves with novel approvals like Vyvgart Hytrulo and HYQVIA, offering patient ...

Results from the PATH study indicate that subcutaneous immunoglobulin is efficacious and well tolerated for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP).

The approval of subcutaneous immunoglobulin (SCIg) in 2006 further revolutionized care, offering patients an alternative prioritizing flexibility and independence. Both modalities remain effective in ...

Finally, subcutaneous immunoglobulin (SCIG), an immunoglobulin treatment administered under the skin, is an alternative treatment you could consider. SCIG can be administered at home and uses a ...

We came across a bullish thesis on KORU Medical Systems, Inc. (KRMD) on Substack by Shareholdersunite. In this article, we will summarize the bulls’ thesis on KRMD. KORU Medical Systems, Inc. (KRMD)’s ...

The agreement is intended for KORU Medical to develop and seek regulatory clearance for a next-generation subcutaneous immunoglobulin (SCIg) therapy infusion system for use with a commercialized ...

The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan. HYQVIA is the first plasma ...

The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan. HYQVIA is the first ...

"Moving to IVIG before the infections start makes much more sense." Banerjee also commented that, in general, "the myeloma field has been moving from IV treatments to subcutaneous treatments to ...

The randomized control trial will assess whether Hizentra, a subcutaneous immunoglobulin treatment, can alleviate symptoms of postural orthostatic tachycardia syndrome, or POTS — a disorder of ...

XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go straight to SCIg without initial intravenous ...